# GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

> **NCT01345253** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 709 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01345253
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-23
- **Primary completion:** 2015-09-15
- **Final completion:** 2018-09-21
- **Target enrollment:** 709 (ACTUAL)
- **Last updated:** 2019-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345253, "GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01345253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*